Table 2 Studies reporting hepatitis C virus (HCV) prevalence among clinical populations in Central Asia (CA).

From: The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses

Author, year (citation)	Year(s) of data collection	Country of survey	Study site	Study design	Study sampling	Population	Sample size	HCV prevalence (%)^a
Non-specific clinical populations
Begaidarova, 2016³⁸	NS	Kazakhstan	Clinical	CS	Conv	HIV patients	181	40.3
Djumagulova, 2016⁸⁵	2004	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	9.0
Djumagulova, 2016⁸⁵	2005	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	8.0
Djumagulova, 2016⁸⁵	2006	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	8.0
Djumagulova, 2016⁸⁵	2007	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	8.0
Djumagulova, 2016⁸⁵	2008	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	8.0
Djumagulova, 2016⁸⁵	2009	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	7.0
Djumagulova, 2016⁸⁵	2010	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	8.0
Djumagulova, 2016⁸⁵	2011	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	8.0
Djumagulova, 2016⁸⁵	2012	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	7.0
Djumagulova, 2016⁸⁵	2013	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	5.9
Djumagulova, 2016⁸⁵	2014	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	19.1
Djumagulova, 2016⁸⁵	2015	Kyrgyzstan	National	CS	Conv	Clinical populations	300^ǂ	33.3
Djumagulova, 2016⁸⁵	2014	Kyrgyzstan	National	CS	Conv	HIV patients	5,505	10.5
Djumagulova, 2016⁸⁵	2015	Kyrgyzstan	National	CS	Conv	HIV patients	6,110	11.5
Asimov, 2015⁴¹	2006–2010	Tajikistan	Community	CS	SRS	HIV patients	109	32.1
Kurbanov, 2003⁴³	2001	Uzbekistan	Clinical	CS	Conv	Hematological disease patients	186	26.9
Ruzibakiev, 2001⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Hematological disease patients	72	29.2
Ruzibakiev, 2001⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Renal disease patients	85	16.5
Djumagulova, 2016⁸⁵	2013	Kyrgyzstan	National	CS	Conv	Recipients (blood, tissue, organs, sperm)	300^ǂ	4.0
Djumagulova, 2016⁸⁵	2014	Kyrgyzstan	National	CS	Conv	Recipients (blood, tissue, organs, sperm)	300^ǂ	4.0
Populations with liver-related conditions
Kurbanov, 2003⁴³	2001	Uzbekistan	Clinical	CS	Conv	Acute hepatitis patients	240	20.0
Kurbanov, 2003⁴³	2001	Uzbekistan	Clinical	CS	Conv	Chronic liver disease patients	234	41.9
Ruzibakiev, 2001⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Acute hepatitis patients	96	16.6
Ruzibakiev, 2001⁸⁹	1999–2000	Uzbekistan	Community	CS	SRS	Chronic liver disease patients	164	26.8
Mirojov, 2013³⁹	NS	Tajikistan	Community	CS	NS	Liver cirrhosis patients	1,374	36.0
Ni, 2012⁹¹	2002–2010	China^¥	Community	CS	Conv	Primary liver cancer patients	335	40.4
Khan, 2008⁴²	2006	Tajikistan	Clinical	CS	Conv	Patients with chronic liver disease	124	46.0
Nersesov, 2017⁹²	2017	Kazakhstan	Clinical	CS	Conv	Hepatocellular carcinoma patients	1,357	23.8
Baimakhanov, 2017⁸⁶	2017	Kazakhstan	Clinical	CS	Conv	Liver transplant patients	64	26.6

Abbreviations: Conv, convenience; CS, cross-sectional; NS, not specified; SRS, simple random sampling;
^aPrevalence figures are as reported in the original reports, but rounded to one decimal place, provided the prevalence figure was over 1%.
^ǂStudy did not report sample size. The included sample size was imputed based on the median sample size of all studies that reported a sample size.
^¥Study performed on immigrants from Central Asia.

Back to article page

Table 2 Studies reporting hepatitis C virus (HCV) prevalence among clinical populations in Central Asia (CA).

Search

Quick links